Mifepristone Tablets
Function and Efficacy
Mifepristone is a receptor-level anti-progestin drug that has the effects of terminating early pregnancy, preventing implantation, inducing menstruation, and promoting cervical ripening. It competes with progesterone for receptors to antagonize progesterone, and also has a certain binding force with glucocorticoid receptors. Mifepristone can significantly increase the sensitivity of the pregnant uterus to prostaglandins. The sequential combination of high-dose mifepristone and prostaglandin drugs can achieve a satisfactory effect of terminating early pregnancy.
Ingredients
Mifepristone. Its chemical name is: 11-[4-(N,N-dimethylamino)]phenyl-17-hydroxy-17-(1-propynyl)-estr-4,9-dien-3-one. Structural formula: Molecular formula: C29H35NO2 Molecular weight: 429.61
| Name | Description | Content | CAS NO. | Manufacturer |
|---|---|---|---|---|
| MifepristoneIngredients |
Receptor-level antiprogesterone drugs have the effects of terminating early pregnancy, preventing implantation, inducing menstruation and promoting cervical ripening. They compete with progesterone for receptors to antagonize progesterone and also have a certain binding force with glucocorticoid receptors. Mifepristone can significantly increase the sensitivity of the pregnant uterus to prostaglandins. The sequential combination of high-dose mifepristone and prostaglandin drugs can achieve a satisfactory effect of terminating early pregnancy. More |
84371-65-3 | 10 |
Appearance
This product is slightly yellow tablet, odorless and tasteless.
Indication
Mifepristone tablets can be used in combination with prostaglandin drugs to terminate pregnancy within 49 days of amenorrhea.
Usage and Dosage
Healthy early pregnant women who have not menstruated for ≤49 days should take 25-50 mg mifepristone tablets orally twice a day on an empty stomach or 2 hours after eating for 2-3 consecutive days, with a total of 150 mg. Fast for 2 hours after each dose. On the morning of the 3rd to 4th day, place a carboprost methyl ester suppository (1 mg) in the posterior fornix of the vagina, or use other similar prostaglandin drugs. Rest in bed for 1-2 hours and be observed in the outpatient clinic for 6 hours. Pay attention to bleeding after medication, the presence of pregnancy products and side effects.
Adverse Reactions
1. Some women in early pregnancy may experience mild nausea, vomiting, dizziness, fatigue, lower abdominal pain, anal distension and uterine bleeding after taking the medicine. 2. Some women may develop rashes. 3. After using prostaglandins, there may be abdominal pain, and some subjects may experience vomiting and diarrhea. A few may experience flushing and numbness.
Precautions
1. Those who are allergic to this product. 2. Those with heart, liver, kidney diseases and adrenal cortex insufficiency. 3. Those who have contraindications to the use of prostaglandins: such as glaucoma, asthma and allergies to prostaglandins. 4. Those who are pregnant with an intrauterine device and suspected ectopic pregnancy, and smoking women over 35 years old
Special Population Medication
Precautions for children: Not yet clear. Precautions for pregnancy and lactation: Contraindicated for pregnant women; the content of mifepristone in breast milk and its effect on infants have not yet been concluded, so it is not recommended for lactating women. Precautions for the elderly: Not yet clear.
Drug Interactions
Avoid taking aspirin and other nonsteroidal anti-inflammatory drugs within 1 week of taking this product.
Storage
Keep away from light and in a dry place.
Packaging Specification
10mg
Validity Period
60 months
Manufacturer
Zhejiang Xianju Pharmaceutical Co., Ltd.
-
Founded in:
2000-06-26 -
Address:
No. 1, Xianyao Road, Xianju County, Taizhou City, Zhejiang Province -
Tax NO.:
913300007047892221 -
Registered Funds:
989.204866 million yuan -
Website:
-
Email: